FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613032309> ?p ?o ?g. }

• W2613032309 endingPage "73722" @default.
• W2613032309 startingPage "73705" @default.
• W2613032309 abstract "// Cody W. Lewis 1, 2, 3 , Zhigang Jin 1, 2, 3 , Dawn Macdonald 1, 2, 3 , Wenya Wei 1 , Xu Jing Qian 1 , Won Shik Choi 1 , Ruicen He 1 , Xuejun Sun 1, 2, 3 and Gordon Chan 1, 2, 3 1 Department of Oncology, University of Alberta, Edmonton, Alberta, Canada T6G 1Z2 2 Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada T6G 1Z2 3 Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Alberta, Canada T6G 2J7 Correspondence to: Gordon Chan, email: gkc@ualberta.ca , gordonch@ahs.ca Keywords: cell cycle checkpoint, Wee1 kinase, paclitaxel, mitotic catastrophe, breast cancer Received: October 21, 2016      Accepted: April 27, 2017      Published: May 13, 2017 ABSTRACT Wee1 kinase is a crucial negative regulator of Cdk1/cyclin B1 activity and is required for normal entry into and exit from mitosis. Wee1 activity can be chemically inhibited by the small molecule MK-1775, which is currently being tested in phase I/II clinical trials in combination with other anti-cancer drugs. MK-1775 promotes cancer cells to bypass the cell-cycle checkpoints and prematurely enter mitosis. In our study, we show premature mitotic cells that arise from MK-1775 treatment exhibited centromere fragmentation, a morphological feature of mitotic catastrophe that is characterized by centromeres and kinetochore proteins that co-cluster away from the condensed chromosomes. In addition to stimulating early mitotic entry, MK-1775 treatment also delayed mitotic exit. Specifically, cells treated with MK-1775 following release from G1/S or prometaphase arrested in mitosis. MK-1775 induced arrest occurred at metaphase and thus, cells required 12 times longer to transition into anaphase compared to controls. Consistent with an arrest in mitosis, MK-1775 treated prometaphase cells maintained high cyclin B1 and low phospho-tyrosine 15 Cdk1. Importantly, MK-1775 induced mitotic arrest resulted in cell death regardless the of cell-cycle phase prior to treatment suggesting that Wee1 inhibitors are also anti-mitotic agents. We found that paclitaxel enhances MK-1775 mediated cell killing. HeLa and different breast cancer cell lines (T-47D, MCF7, MDA-MB-468 and MDA-MB-231) treated with different concentrations of MK-1775 and low dose paclitaxel exhibited reduced cell survival compared to mono-treatments. Our data highlight a new potential strategy for enhancing MK-1775 mediated cell killing in breast cancer cells." @default.
• W2613032309 created "2017-05-19" @default.
• W2613032309 creator A5011363099 @default.
• W2613032309 creator A5015393043 @default.
• W2613032309 creator A5039784240 @default.
• W2613032309 creator A5053001415 @default.
• W2613032309 creator A5057415739 @default.
• W2613032309 creator A5066700813 @default.
• W2613032309 creator A5072801522 @default.
• W2613032309 creator A5075138829 @default.
• W2613032309 creator A5085269203 @default.
• W2613032309 date "2017-05-13" @default.
• W2613032309 modified "2023-10-02" @default.
• W2613032309 title "Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel" @default.
• W2613032309 cites W1131868295 @default.
• W2613032309 cites W1540858422 @default.
• W2613032309 cites W1967019500 @default.
• W2613032309 cites W1972163440 @default.
• W2613032309 cites W1972415133 @default.
• W2613032309 cites W1981494266 @default.
• W2613032309 cites W1988996363 @default.
• W2613032309 cites W1994107958 @default.
• W2613032309 cites W1995068068 @default.
• W2613032309 cites W1999074203 @default.
• W2613032309 cites W2003455873 @default.
• W2613032309 cites W2006262026 @default.
• W2613032309 cites W2007877171 @default.
• W2613032309 cites W2022239608 @default.
• W2613032309 cites W2023264140 @default.
• W2613032309 cites W2026143081 @default.
• W2613032309 cites W2030864103 @default.
• W2613032309 cites W2039428192 @default.
• W2613032309 cites W2046024621 @default.
• W2613032309 cites W2048109276 @default.
• W2613032309 cites W2057991981 @default.
• W2613032309 cites W2061730009 @default.
• W2613032309 cites W2068973642 @default.
• W2613032309 cites W2071259832 @default.
• W2613032309 cites W2071359790 @default.
• W2613032309 cites W2075152619 @default.
• W2613032309 cites W2080893860 @default.
• W2613032309 cites W2091400998 @default.
• W2613032309 cites W2096167430 @default.
• W2613032309 cites W2096293110 @default.
• W2613032309 cites W2098037687 @default.
• W2613032309 cites W2100577737 @default.
• W2613032309 cites W2105712639 @default.
• W2613032309 cites W2111222453 @default.
• W2613032309 cites W2113283898 @default.
• W2613032309 cites W2127136362 @default.
• W2613032309 cites W2129899300 @default.
• W2613032309 cites W2134435988 @default.
• W2613032309 cites W2146823569 @default.
• W2613032309 cites W2148594307 @default.
• W2613032309 cites W2154603906 @default.
• W2613032309 cites W2154966585 @default.
• W2613032309 cites W2166283261 @default.
• W2613032309 cites W2171251720 @default.
• W2613032309 cites W2176143223 @default.
• W2613032309 cites W2227835616 @default.
• W2613032309 cites W2312266417 @default.
• W2613032309 cites W2470708296 @default.
• W2613032309 doi "https://doi.org/10.18632/oncotarget.17848" @default.
• W2613032309 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5650293" @default.
• W2613032309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29088738" @default.
• W2613032309 hasPublicationYear "2017" @default.
• W2613032309 type Work @default.
• W2613032309 sameAs 2613032309 @default.
• W2613032309 citedByCount "40" @default.
• W2613032309 countsByYear W26130323092018 @default.
• W2613032309 countsByYear W26130323092019 @default.
• W2613032309 countsByYear W26130323092020 @default.
• W2613032309 countsByYear W26130323092021 @default.
• W2613032309 countsByYear W26130323092022 @default.
• W2613032309 countsByYear W26130323092023 @default.
• W2613032309 crossrefType "journal-article" @default.
• W2613032309 hasAuthorship W2613032309A5011363099 @default.
• W2613032309 hasAuthorship W2613032309A5015393043 @default.
• W2613032309 hasAuthorship W2613032309A5039784240 @default.
• W2613032309 hasAuthorship W2613032309A5053001415 @default.
• W2613032309 hasAuthorship W2613032309A5057415739 @default.
• W2613032309 hasAuthorship W2613032309A5066700813 @default.
• W2613032309 hasAuthorship W2613032309A5072801522 @default.
• W2613032309 hasAuthorship W2613032309A5075138829 @default.
• W2613032309 hasAuthorship W2613032309A5085269203 @default.
• W2613032309 hasBestOaLocation W26130323091 @default.
• W2613032309 hasConcept C105696609 @default.
• W2613032309 hasConcept C120504264 @default.
• W2613032309 hasConcept C121608353 @default.
• W2613032309 hasConcept C126322002 @default.
• W2613032309 hasConcept C186000732 @default.
• W2613032309 hasConcept C2778437423 @default.
• W2613032309 hasConcept C2781252693 @default.
• W2613032309 hasConcept C29537977 @default.
• W2613032309 hasConcept C502942594 @default.
• W2613032309 hasConcept C530470458 @default.
• W2613032309 hasConcept C71924100 @default.
• W2613032309 hasConcept C86803240 @default.

• next